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Abstract
Objectives. To assess the prevalence and severity of inflammatory abnormalities of the hand, wrist and
foot joints in SLE patients by US and to correlate them with clinical, laboratory and disease activity score
parameters.
Methods. Sixty-two consecutive SLE patients were enrolled in the present study and underwent clinical
evaluation, laboratory tests and bilateral high-resolution US of the hand, wrist and foot joints. Joint effu-
sion (JE), synovial hypertrophy (SH) and local pathological vascularization [power Doppler (PD)] were
evaluated according to both a dichotomous score and a semi-quantitative (03) grading system. In add-
ition, a global US score was calculated by summing the values given to each elementary lesion for every
single joint and every joint group. US findings were correlated with physical examination, serological
parameters (CRP, ANA, anti-dsDNA, ENA, aPL, C3 and C4 serum levels) and disease activity indexes
(SLEDAI-2K, ECLAM).
Results. US detected inflammatory joint abnormalities in 54/62 patients (87.1%); 72.6% presented in-
volvement of the MTP joints, 46.7% the MCP joints, 19.3% the PIP joints and 53% the wrists. A total of
1984 joints were examined highlighting JE in 19.1% of cases, SH in 6.9% and positive PD in 1.1%. The
global US inflammatory score had a mean value of 10.9 (S.D. 15.2). No correlations were found between
US findings and SLE disease activity parameters.
Conclusion. US demonstrated a high prevalence of inflammatory joint abnormalities in SLE that were also
present in asymptomatic patients. Interestingly, the foot joints were the most frequently involved. US is a
valuable tool for detecting subclinical synovitis in SLE.
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Introduction
SLE is a chronic inflammatory disorder with a multifactor-
ial aetiology in which genetic and environmental factors
interact in disease susceptibility [1, 2]. Key features of the
disease are autoimmunity alterations, characterized
by the production of a wide range of autoantibodies
[35]. SLE mainly affects women of reproductive age
and every organ and/or system can be involved in the
pathological process [1, 6]. Among them, involvement
of the musculoskeletal system is most frequent and
often the earliest manifestation of SLE, occurring in up
to the 94% of patients during the course of the disease
[7]. The joint involvement is characterized by heterogenic
features such as arthralgia, arthritis and, more rarely, as
deforming arthropathy, known as Jaccoud arthropathy [7].
In recent years, the monitoring of disease activity by using
specific composite indices has become an important
aspect in the management of patients affected by SLE
[8]. Moreover, new therapeutic approaches have been
introduced, further highlighting the need for different
tools able to evaluate disease activity and treatment
efficacy [9].
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In view of the high frequency of joint involvement in SLE
patients, the application of specific instruments to assess
this feature is recommended. Musculoskeletal US has
been proven to be a useful imaging technique that helps
in correlating clinical and anatomical findings, providing
relevant information that might influence management of
the disease [10, 11]. US is able to depict synovial and
tenosynovial inflammation as well as structural damage
lesions [10]. Moreover, the application of power Doppler
(PD) has improved the sensitivity of US in detecting active
inflammation through the identification of pathologically
increased haematic perfusion [12]. US has been applied
in several rheumatic inflammatory diseases [1318].
However, only a few studies have been focused on the
assessment of SLE patients using US [1923].
The aim of the present study was to evaluate joint in-
flammatory abnormalities of the hand, wrist and foot joints
in SLE patients using US and PD. Imaging findings were
correlated with clinical, laboratory and disease activity
score parameters.
Patients and methods
Patients affected by SLE, diagnosed according to the
1997 revised ACR criteria, were consecutively enrolled in
the study [24]. All of them were in the in- and outpatient
population attending the Lupus Clinic of the
Rheumatology Unit of Sapienza Universita` di Roma,
Italy. The study was conducted according to the protocol
and good clinical practice principles and Declaration of
Helsinki statements. All patients gave their informed con-
sent and the study was approved by the Comitato Etico
Sapienza Universita` di Roma, Policlinico Umberto I,
Rome, Italy.
The study protocol included complete physical examin-
ation, blood draws and ultrasonographic assessment. The
clinical and laboratory data were collected in a standar-
dized computerized electronically filled form, including
demographics, past medical history with date of diagno-
sis, co-morbidities and previous and concomitant treat-
ments. In particular, joint involvement of the wrists,
hands and feet was defined as the presence of pain
and/or swelling and/or functional impairment in the re-
ported medical history or at the physical examination.
Clinical activity was assessed using the SLEDAI 2000
(SLEDAI-2K) and the ECLAM [8, 25]. Each subject under-
went peripheral blood sample collection. The sera re-
covered were then stored at 20C until assayed. CRP
was assessed by nephelometry (mg/l). ANA was deter-
mined by means of IIF on HEp-2 and anti-dsDNA by IIF
on Crithidia luciliae in accordance with the manufacturer’s
instructions (Orgentec Diagnostika, Mainz, Germany).
ENA (anti-Ro/SSA, anti-La/SSB, anti-Sm, anti-RNP) anti-
CL (IgG and IgM isotype) and anti-b2GPI (IgG and IgM
isotype) were determined by ELISA (Diamedix, Miami,
FL, USA), and LA was assessed according to the guide-
lines of the International Society on Thrombosis and
Hemostasis (Scientific Subcommittee on LA/phospho-
lipid-dependent antibodies). In all patients, C3 and C4
serum levels (mg/dl) were studied by using radial
immunodiffusion.
On the same day as the clinical evaluation, all patients
underwent an ultrasonographic assessment at the US unit
of the same department. A single rheumatologist, expert
in musculoskeletal US, who was blinded to clinical and
laboratory data, performed the examination and scored
the static images. A MyLab70 XVision Gold (Esaote,
Genova, Italy) machine equipped with a multifrequency
linear array transducer (618 MHz) was used. PD settings
were PD pulse repetition frequency 750 Hz, Doppler fre-
quency 11.1 MHz, gain 50% and low filters. A systematic
bilateral multiplanar grey-scale and PD examination,
including both dorsal and palmar scans, of the hand
(MCP and PIP joints), wrist and foot joints (MTP joints),
was performed according to international guidelines for
musculoskeletal US in rheumatology [26]. Specifically, at
the wrist level, the radiocarpal and ulnocarpal joints were
evaluated, performing longitudinal and transverse scans
over the dorsal and volar aspects of the joints. Both
joints were scored and the one that presented the highest
score was considered for final radioulnocarpal (RUC) joint
score at the wrist level.
Every joint was examined in order to identify signs of
synovitis, i.e. joint effusion, synovial hypertrophy and PD
signal. All abnormalities were defined according to the
OMERACT definitions for ultrasonographic pathology
[27]. US-detected elementary lesions were primary eval-
uated with a dichotomous score (absence or presence)
and then graded according to a semi-quantitative scale
ranging from 0 to 3 (0 = absent, 1 = mild, 2 = moderate and
3 = severe). Then, ultrasonographic inflammatory scores,
calculated by adding the values given to each elementary
lesion, were elaborated for every single joint and every
joint group (MTP, MCP, PIP wrist joints). Finally, a global
score was obtained by adding together the scores for all
joint groups. All data were reported on the electronic
database.
Statistical analysis
Statistical analysis was performed using SPSS statistical
software (version 13.0; SPSS, Chicago, IL, USA). Chi-
square and Fisher’s exact test were used to compare
qualitative differences between joint groups, while
Wilcoxon’s test (MannWhitney U-test) was performed
to compare parametric variables. The findings were
expressed as the mean (S.D.). Values of P <0.05 were
considered to be statistically significant.
Results
Sixty-two consecutive patients (58 females and 4 males)
were included in the study. The demographic, clinical,
laboratory and therapeutic parameters of the enrolled
subjects are reported in Table 1.
Ultrasonographic findings
The US findings related to joint inflammatory abnormal-
ities (joint effusion and/or synovial hypertrophy and/or PD)
466 www.rheumatology.oxfordjournals.org



















were observed in 54 of 62 (87.1%) patients. Only 25 pa-
tients of these 54 presented articular involvement at the
clinical examination and 29 of these showed US signs of
inflammation in the absence of clinical joint disease. In
particular, US inflammatory changes were at least de-
tected in a single RUC in 33/62 (53%) patients, in an
MCP in 29/62 (46.7%), in a PIP in 12/62 (19.3%) and in
an MTP in 45/62 (72.6%), as shown in Fig. 1. According to
these findings, MTP joints were the most frequently
involved site, with statistically significant differences with
respect to RUC (P= 0.005), MCP (P= 0.0003) and PIP
(P< 0.000001) joints. In the MCP group the most com-
monly involved joint was the second MCP, presenting at
least one US alteration in 20/62 (32.2%) patients, followed
in descending order by the third MCP, which showed US
inflammatory signs in 30.6% of patients, the first MCP in
20.9%, the fifth MCP in 22.6% and the fourth MCP in
19.3%. In the PIP joints, the third PIP was the most fre-
quently involved (12.9% patients). The first and second
PIP joints showed US abnormalities each in 11% of pa-
tients, the fifth PIP in 9.6% and the fourth PIP in 8.1%. In
the MTP joints, the second MTP had US-detected involve-
ment in 61.3% patients, the third MTP in 51.6%, the first
MTP in 45.2%, the fourth MTP in 40.3% and the fifth MTP
in 17.7% (Fig. 2).
A total of 1984 joints were studied by US. The most
prevalent abnormal US finding was joint effusion, which
was detected in 378/1984 joints (19.1%). Synovial hyper-
trophy was demonstrated in 138/1984 joints (6.9%)
and PD signal was positive in 22/1984 joints (1.1%).
The global US inflammatory score had a mean value of
10.9 (S.D. 15.2). The analysis of each articular group
showed that the MTP joints presented the highest US
score, followed by the MCP, RUC and PIP joints, as
shown in Table 2. Specifically, the mean RUC score was
1.8 (S.D. 2.6), the mean MCP was 3.3 (S.D. 7.4), the mean
PIP was 1.24 (S.D. 5.3) and the mean MTP was 4.5
(S.D. 5.2).
TABLE 1 Demographic, clinical, laboratory and therapeutic characteristics of SLE patients:
cumulative and at the time of US evaluation
Cumulative
At the time of the
US evaluation
Female/male, n 58/4
Age, mean (S.D.), years — 42.8 (12.9)
Disease duration, mean (S.D.), months — 134.7 (112.5)
Joint involvement, n (%) 56 (90.3) 25 (40)
Skin involvement, n (%) 50 (80.6) 8 (12.9)
Renal involvement, n (%) 21 (33.8) 8 (12.9)
Serositis, n (%) 14 (22.6) 0 (0)
Neuropsychiatric involvement, n (%) 9 (14.5) 1 (1.6)
Cytopenia, n (%) 40 (64.5) 10 (16.1)
Laboratory parameters
CRP, mean (S.D.), mg/l 5.2 (4.7)
ANA, n (%) 51 (82.2) 44 (70.9)
Anti-dsDNA, n (%) 43 (69.3) 15 (24.2)
Anti-Sm, n (%) 15 (24.2) 4 (6.4)
Anti-SSA, n (%) 23 (37.1) 12 (19.3)
Anti-SSB, n (%) 13 (20.9) 5 (8.1)
Anti-RNP, n (%) 14 (22.6) 6 (9.7)
Anti-cardiolipin IgG and/or IgM, n (%) 31 (50.0) 3 (4.8)
Anti-b2GPI IgG and/or IgM, n (%) 9 (14.5) 1 (1.6)
LA, n (%) 14 (22.6) 1 (1.6)
Low C3 and/or C4 levels, n (%) 28 (45.2) 22 (35.5)
C3, mean (S.D.), mg/dl — 65.5 (47.5)
C4, mean (S.D.), mg/dl — 12.3 (10.8)
Treatment
Glucocorticoids, n (%) 57 (91.9) 46 (74)
Glucocorticoids, mean weekly dosage (S.D.), mg — 51.3 (34.8)
HCQ, n (%) 55 (90.1) 42 (67.7)
MTX, n (%) 22 (35.5) 7 (11.3)
AZA, n (%) 16 (25.8) 5 (8.1)
Mycophenolate, n (%) 20 (32.2) 10 (16.1)
Ciclosporin A, n (%) 20 (32.2) 7 (11.3)
CYC, n (%) 11 (17.7) 1 (1.6)
Rituximab, n (%) 3 (4.8) 1 (2)
SLEDAI-2K, mean (S.D.) — 2.3 (2.9)
ECLAM, mean (S.D.) — 0.9 (1)
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The US score was significantly higher in MTP joints than
in MCP (P= 0.0029) and PIP (P= 0.0001) joints, showing
that MTP joints were the most severely involved articular
site (Fig. 3). In particular, among the 620 MTP joints eval-
uated, 160/620 (25.8%) presented only joint effusion and
41/620 (46.6%) presented both joint effusion and syno-
vitis. Supplementary Fig. S1, available at Rheumatology
Online, illustrates examples of grey-scale and PD US
synovitis in the MTP and RUC joints of patients with SLE.
At the patient level, RUC joint effusion was detected in
14/62 (22.6%) patients, RUC joint synovial hypertrophy
without PD in 11/62 (17.7%) and RUC joint synovial hyper-
trophy with PD in 7/62 (11.3%). In the MCP joints, 15/62
patients (24.2%) presented only joint effusion, 6/62 (9.7%)
FIG. 1 Histograms representing the frequency of joint inflammatory involvement detected by US in the four articular
groups (RUC, MCP, PIP and MTP).
The 62 SLE patients included in the study were subgrouped according to the presence or absence of clinical mani-
festations (Group A and Group B, respectively). RUC-A, radioulnocarpal joints Group A; RUC-B, radioulnocarpal joints
Group B; MCP-A, metacarpophalangeal joints Group A; MCP-B, metacarpophalangeal joints Group B; PIP-A, proximal
interphalangeal joints Group A; PIP-B, proximal interphalangeal joints Group B; MTP-A, metatarsophalangeal joints
Group A; MTP-B, metatarsophalangeal joints Group B.
FIG. 2 Histogram showing the frequency of inflammatory involvement detected by US at different joint sites.
The MCP joints (1st5th), PIP joints (1st5th) and MTP joints (1st5th) were assessed in the 62 patients affected by SLE
included in the study.
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synovial hypertrophy without PD and 6/62 (9.7%) synovial
hypertrophy with PD. In the PIP joints, 6/62 (9.7%) pa-
tients presented only joint effusion, 4/62 (6.5%) synovial
hypertrophy without PD and 2/62 (3.2%) synovial hyper-
trophy with PD. Finally, in the MTP joints, 31/62 (50%)
patients presented only joint effusion, 10/62 (16%) syn-
ovial hypertrophy without PD and 3/62 (4.8%) synovial
hypertrophy with PD.
The possible presence of a concomitant condition of
OA was evaluated. The US signs of initial OA (mild osteo-
phytes) at the PIP, first MCP and first MTP joints were
detected in only 4/62 patients (6.5%) and in these joints
there was no effusion or synovial hypertrophy.
Correlation between clinical/laboratory and
ultrasonographic data
For the analysis of the correlations between clinical data
and ultrasonographic findings of joint involvement, pa-
tients were divided into two subgroups, according to the
presence or absence of clinical joint involvement, con-
sidered as the presence of joint pain associated or not
with articular swelling at examination time. The first
subgroup included 40.3% patients showing a clinical
joint involvement (Group A) and the second group was
TABLE 2 Global ultrasonographic inflammatory scores









aThe MTP joints presented the highest US score, followed
by the MCP, RUC and PIP joints.
FIG. 3 Mean ultrasonographic inflammatory score at different joint sites.
The scores were calculated at the MCP, PIP and MTP joints in (A) the group of SLE patients,(B) patients in Group A and
(C) patients in Group B.
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composed of 59.7% patients without joint manifestations
(Group B).
The global US inflammatory score obtained in Group A
presented a mean value of 17.5 (S.D. 20.8), which was
significantly higher than the score obtained in Group B
(P= 0.009). Similarly, US inflammatory scores calculated
for the RUC and MCP joints were significantly higher in
Group A than in Group B (P= 00003 and P= 0.002,
respectively). No significant differences were found
among US inflammatory scores of the PIP and MTP
joints (Table 3). The analysis of the correlations between
CRP levels and US total score found significant results
(R= 0.3, P= 0.01).
Finally, no correlations were highlighted between US
findings and SLEDAI-2K and ECLAM. Similarly, no correl-
ation was demonstrated between US findings and the
autoantibodies tested (data not shown).
Discussion
Several studies have demonstrated that ultrasonography
is a useful imaging modality in the assessment of a wide
range of abnormalities in rheumatic diseases [2832].
In particular, RA and SpA have been extensively
investigated by musculoskeletal US, mostly for the ana-
lysis of US-detected inflammatory lesions [33, 34].
However, very few US studies have focused on the as-
sessment of musculoskeletal abnormalities in SLE, even
though joint involvement is the most common feature in
SLE patients [11, 1922].
To the best of our knowledge, this is the first US study
aimed at analysing inflammatory changes in the foot
(MTP) joints in SLE patients. We found that MTP joints
were the most frequently involved site (72.6% of patients)
compared with the wrist, MCP and PIP joints. The MTP
joints are considered a target joint in RA and their assess-
ment by US has been extensively investigated in a number
of studies that demonstrated its sensitivity in detecting
joint inflammation, even when compared with other ima-
ging techniques such as magnetic resonance [3537]. The
evidence of high US inflammatory scores for joint lesions
in the presence of bony erosions involving, in particular,
the fifth MTP has been described as a suggestive element
for RA [38]. In the present study, US inflammatory scores
calculated to quantify the severity of local joint inflamma-
tion presented the highest values for the MTP joints, with
statistically significant differences with respect to the
MCP and PIP joints. These innovative results seems to
indicate that, as well as in RA, the MTP joints may be a
target area of inflammation in SLE and might be suggest-
ive of similar inflammatory features at the joint level in the
two diseases. However, these findings need further
investigation.
At the hand and wrist joint level, our results are essen-
tially in agreement with those obtained by previous
researchers [11, 2023]. In particular, different aspects
of US synovitis have been previously reported in the
RUC, MCP and PIP joints of SLE patients [20, 21]. Our
results confirmed that, in the hand and wrist, the RUC
joints are the most commonly involved site in SLE pa-
tients, followed by the MCP and PIP joints. US-detected
abnormalities at this level, including signs of mild syno-
vitis, were seen in a large number of patients in our study
and, as recently reported, may be related to conditions of
wrist arthralgia [39].
SLE is a prototype of systemic autoimmune diseases
with a wide range of clinical features and serum autoanti-
bodies [1, 40]. The disease is characterized by heteroge-
neous degrees of severity as well as unpredictable
disease flares and remissions [4042]. Overall, the mus-
culoskeletal system is the most common and often the
earliest manifestation of SLE. In our study, the presence
of at least a single US abnormality was detected in the
majority of patients (87.1%), supporting the concept of a
high prevalence of joint involvement in SLE. However, only
40% of our patients presented clinical features of
joint involvement at the time of evaluation, and in all of
them US confirmed the presence of inflammatory joint
conditions. This dissociation between clinical and US ima-
ging findings is suggestive of a condition of subclinical
synovitis and has already been reported in several
studies performed in different rheumatic diseases, stres-
sing the concept of a greater sensitivity of US in detecting
inflammation when compared with clinical evaluation
[4345].
The lack of correlation between US findings and the
SLEDAI-2K and ECLAM, as highlighted in the present
study, suggests the need for a global assessment of
SLE patients that might even include imaging modalities,
such as US, in order to better classify joint inflammatory
conditions and avoid the risk of underestimating subclin-
ical inflammatory abnormalities. SLEDAI-2K and ECLAM






(Group B, n=37) P-value
Total score, mean (S.D.) 17.5 (20.8) 6.6 (7.2) 0.009
RUC score, mean (S.D.) 3 (2.8) 1.02 (2.2) 0.0003
MCP score, mean (S.D.) 2 (10.4) 1.1 (2.4) 0.002
PIP score, mean (S.D.) 2.9 (8.2) 0 (0.3) 0.06
MTP score, mean (S.D.) 4.8 (5.3) 4.4 (5.3) 0.09
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lack the sensitivity to identify local disease inflammation
activity at the joint level because the presence of joint
disease without signs of systemic or major organ involve-
ment is not systematically analysed in these composite
indices.
Additional applications of musculoskeletal US to SLE
patients have been recently developed, using this imaging
technique in paediatric patients and to monitor biologic
therapy [46, 47].
US has many advantages over other imaging modal-
ities, as it is safe, inexpensive and well accepted by
patients. In the future, further development of US technol-
ogies might broaden the potential uses of this imaging
technique, adding relevant information to the diagnostics
and monitoring of rheumatic diseases such as SLE
[4850].
In conclusion, three key points emerge from the present
study: the unexpected involvement of the MTP joints in
SLE patients, the demonstration of subclinical articular
abnormalities in a consistent percentage of SLE patients
and the absence of correlation between US and SLE dis-
ease activity scores. The results presented in this study
suggest the inclusion of US in the assessment of SLE
patients in order to better assess joint pathology, adding
useful information not easily gained by clinical
examination.
Rheumatology key messages
. Unexpected involvement of the MTP joints in SLE
patients was found by US.
. Subclinical articular abnormalities were seen in a
consistent percentage of SLE patients.
. The absence of correlations between US and SLE
disease activity scores was demonstrated.
Disclosure statement: The authors have declared no
conflicts of interest.
Supplementary data
Supplementary data are available at Rheumatology
Online.
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